<SEC-DOCUMENT>0001144204-19-025280.txt : 20190510
<SEC-HEADER>0001144204-19-025280.hdr.sgml : 20190510
<ACCEPTANCE-DATETIME>20190510162353
ACCESSION NUMBER:		0001144204-19-025280
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190510
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190510
DATE AS OF CHANGE:		20190510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		19815264

	BUSINESS ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219
		BUSINESS PHONE:		2149055100

	MAIL ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv521288_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT PURSUANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO SECTION 13 OR 15(D) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
<B>May 10, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B><U>ABEONA
THERAPEUTICS INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Delaware</U></B></FONT></TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>001-15771</U></B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>83-0221517</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1330 Avenue of the Americas, 33<SUP>rd</SUP>
Floor, </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>New York, NY 10019</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>(646) 813-4712</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>N/A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see<I>&nbsp;</I>General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Emerging growth company <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">Securities
registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 27%; border-bottom: Black 1pt solid; padding-right: -1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 7%; padding-right: -1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; border-bottom: Black 1pt solid; padding-right: -1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 5%; padding-right: -1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: Black 1pt solid; padding-right: -1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -1pt; text-align: center">Common Stock, $0.01 par value</TD>
    <TD STYLE="padding-right: -1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: -1pt; text-align: center">ABEO</TD>
    <TD STYLE="padding-right: -1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: -1pt; text-align: center">Nasdaq Capital Markets</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2.02.&nbsp;&nbsp;Results of Operations and Financial
Condition. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 10, 2019, Abeona Therapeutics Inc.
issued a press release regarding its results of operations and financial condition for the quarter ended March 31, 2019. The full
text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in Item&nbsp;2.02 of this
Current Report on Form&nbsp;8-K and Exhibit&nbsp;99.1 attached hereto shall not be deemed &ldquo;filed&rdquo; for purposes of Section&nbsp;18
of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Financial Statements
and Exhibits. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt"><B><U>Exhibit No.</U></B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B><U>Description</U></B></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; width: 10%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; width: 88%; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt"><A HREF="tv521288_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><A HREF="tv521288_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press release dated May 10, 2019, entitled &ldquo;Abeona Therapeutics Reports First Quarter 2019 Financial Results and Business Highlights&rdquo;</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="width: 45%; text-align: justify"><FONT STYLE="font-size: 10pt">May 10, 2019</FONT></TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 47%; text-align: justify"><FONT STYLE="font-size: 10pt"><U>/s/ Christine Silverstein </U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Christine Silverstein</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv521288_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">Exhibit 99.1</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Abeona Therapeutics Reports First Quarter
2019 Financial Results and Business Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CMC work completed in advance of EB-101
Phase 3 VITAL&trade; trial expected to begin mid-2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">IND submitted for ABO-202 in CLN1 disease</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Investor conference call on Tuesday, May
14 at 10:00 a.m. ET</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEW YORK and CLEVELAND, May 10, 2019 --
Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced first quarter 2019
financial results and business highlights, which will be discussed on a conference call scheduled for Tuesday, May 14 at 10:00
a.m. ET. Interested parties are invited to participate in the call by dialing 844-369-8770 (toll-free domestic) or 862-298-0840
(International) or via webcast at <FONT STYLE="color: Blue"><U>https://www.investornetwork.com/event/presentation/48814</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We&rsquo;ve had a great start to
2019, with continued progress across our pipeline, including the completion of CMC work in advance of initiating our Phase 3 VITAL&trade;
clinical trial evaluating EB-101, our gene-corrected cell therapy for patients with recessive dystrophic epidermolysis bullosa,&rdquo;
said Jo&atilde;o Siffert, M.D., Chief Executive Officer. &ldquo;The study, which will utilize clinical material produced at our
Cleveland manufacturing facility, is on track to start mid-2019 following completion of ongoing FDA review.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We have continued to advance our
lysosomal storage disease programs. Our increased efforts around patient recruitment are starting to bear fruit as we observe an
uptick in patient screening for both MPS programs. In addition, we have submitted the IND for our CLN1 program.&rdquo; added Dr.
Siffert.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>First Quarter Financial Results:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash, cash equivalents and marketable securities
as of March 31, 2019 were $68.3 million, compared to $85.0 million as of December 31, 2018. The decrease in cash of $16.7 million
was driven primarily by the net cash used for operating activities of $15.1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses for the
first quarter ended March 31, 2019 were $11.7 million, compared to $8.2 million for first quarter 2018. The increase in research
and development expense was primarily attributable to increased R&amp;D headcount, related facility costs and internal manufacturing
costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses for
the first quarter ended March 31, 2019 were $5.7 million, compared to $2.9 million for the first quarter 2018. The increase in
general and administrative expenses was primarily attributable to increased headcount and related facility costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net loss was $0.39 per share for the first
quarter of 2019, compared to $0.22 per share in the same period of 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt; text-align: right"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right">Exhibit 99.1</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>First Quarter and Recent Highlights:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">May 8, 2019: Abeona Therapeutics Announces
Presentation of EB-101 Data at Society for Investigative Dermatology Annual Meeting</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Follow up data showed that three years after treatment with investigational product, EB-101, a
majority of RDEB patients had durable wound healing and improvements in pain and itching. There were no serious treatment-related
adverse events three years post-treatment and no replication competent virus present at any time point.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">May 1, 2019: Reported Preclinical Data
Demonstrating Broad Therapeutic Potential of AIM&trade; Gene Therapy in Retinal Diseases at Association for Research in Vision
and Ophthalmology Annual Meeting</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Intravitreal administration of the Company&rsquo;s novel AIM&trade; AAV204 capsid in non-human
primates led to robust transgene expression in the inner and outer retina. These preclinical data support the potential use of
intravitreal administration to deliver gene therapy in an out-patient setting for a wide range of inherited and acquired retinal
diseases.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">April 30, 2019: Reported New Preclinical
Data Demonstrating Therapeutic Potential of ABO-401 for Treatment of Cystic Fibrosis at American Society of Gene and Cell Therapy
Annual Meeting</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">ABO-401, the Company&rsquo;s novel gene therapy for cystic fibrosis (CF) efficiently delivered
a highly-expressed, functional copy of human mini-CFTR (hCFTR) to the lung of CF mice and restored CFTR function in human CF patient
nasal and bronchial epithelial cells.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">April 4, 2019: Received FDA Fast Track
Designation for ABO-101 for Treatment of Sanfilippo Syndrome Type B (MPS IIIB)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">February 11, 2019: Appointed Jo&atilde;o
Siffert, M.D. Chief Executive Officer</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">January 31, 2019: Presented New Supportive
Data for Novel Gene Therapies at WORLDSymposium&trade;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Platform and poster presentations highlighted study results on biodistribution and tissue tropism
of the next-generation AIM&trade; AAV vector platform in Pompe and Fabry diseases, as well as data from programs in MPS IIIA and
CLN3 disease.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">January 8, 2019: Strengthened Financial
Leadership with New Executive Appointments: Christine Silverstein as Chief Financial Officer and Edward Carr as Chief Accounting
Officer</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We expect 2019 to be a transformative
year for Abeona, as we prepare to execute on a number of milestones in the clinic, in our mission to develop gene and cell therapies
that could transform the treatment of serious diseases,&rdquo; said Steven H. Rouhandeh, Chairman of the Board and Executive Chairman.
 &ldquo;We are encouraged to continue advancing the proprietary technology of our AIM&trade; vector platform, especially following
recent promising data presented across multiple indications, for which we continue to evaluate avenues of development internally,
and with potential partners.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify"><B>About Abeona Therapeutics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">Abeona
Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. The Company&rsquo;s
clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa,
as well as ABO-102 and ABO-101, novel NAV AAV9-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and
MPS IIIB), respectively. The Company&rsquo;s portfolio of AAV9-based gene therapies also features ABO-202 and ABO-201 for CLN1
disease and CLN3 disease, respectively. Its preclinical assets include ABO-401, which uses the novel AIM&trade; AAV vector platform
to address all mutations of cystic fibrosis. Abeona has received numerous regulatory designations from the FDA and EMA for its
pipeline candidates and is the only company with Regenerative Medicine Advanced Therapy designation for two candidates (EB-101
and ABO-102). For more information, visit </FONT><FONT STYLE="color: Blue"><U>www.abeonatherapeutics.com</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt; text-align: right"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right">Exhibit 99.1</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify"><B>Forward Looking Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains certain statements
that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, and that involve risks and uncertainties. These statements include but are not limited to statements
related to our estimates regarding expenses, future revenues, capital requirements, and needs for additional financing; our ability
to raise capital; our ability to fund our operating expenses and capital expenditure requirements for at least the next 12&nbsp;months
with our existing cash and cash equivalents; our expectation that we will continue to incur losses; our belief that we will expend
substantial funds to conduct research and development programs; our future ability to achieve profitability at all or on a sustained
basis; our cash burn rate; the dilutive effect that raising additional funds by selling additional equity securities would have
on the relative equity ownership of our existing investors; our belief that we have a rich pipeline of products and product candidates;
our ability to continue to develop our novel adeno-associated virus (&ldquo;AAV&rdquo;)-based gene therapy platform technology
to treat neurologic disorders, cystic fibrosis and eye disorders in human subjects; our belief that EB-101 could potentially benefit
patients with recessive dystrophic epidermolysis bullosa (&ldquo;RDEB&rdquo;); positive feedback from regulators on our manufacturing
of clinical trial product for EB-101; our ability to initiate a Phase III clinical trial for patients with RDEB; our ability to
complete enrollment of patients into clinical trials to secure sufficient data to assess efficacy and safety; our belief that AAV
treatment could potentially benefit patients with Sanfilippo syndrome type A (&ldquo;MPS IIIA&rdquo;) and Sanfilippo syndrome type
B (&ldquo;MPS IIIB&rdquo;); our ability to add clinical sites and identify additional patients for our Phase I/II clinical trial
for patients with MPS IIIA and MPS IIIB; our ability to continue to secure and maintain regulatory designations for our product
candidates; our ability to develop manufacturing capability compliant with current good manufacturing practices for our product
candidates; our ability to manufacture gene therapy products and produce an adequate product supply to support clinical trials
and potentially future commercialization; our ability to secure timely regulatory review related to our clinical program; our belief
in the adequacy of the data from clinical trials in EB-101 and expansion cohort of our Phase I/II clinical trial in ABO-102 (AAV-SGSH)
for MPS IIIA, together with the data generated in the program to date, to support regulatory approvals; our intellectual property
position and our ability to obtain, maintain and enforce intellectual property protection and exclusivity for our proprietary assets;
the rate and degree of market acceptance of our product candidates for any indication once approved; our estimates regarding the
size of the potential markets for our product candidates, the strength of our commercialization strategies and our ability to serve
and supply those markets; our ability to meet our obligations contained in license agreements to which we are party; and the terms
of future licensing arrangements or collaborations. We have attempted to identify forward looking statements by such terminology
as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
 &ldquo;intend,&rdquo; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances),
which constitute and are intended to identify forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify">Actual results may differ materially
from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties,
including but not limited to: continued interest in our rare disease portfolio, our ability to submit protocols and protocol amendments
to regulatory agencies, our ability to initiate and enroll patients in clinical trials, the adequacy of manufacturing capabilities,
the impact of competition, the ability to secure licenses or establish intellectual property rights for any technology that may
be necessary to continue to develop and commercialize our products, the ability to achieve or obtain necessary regulatory approvals,
the impact of changes in the financial markets and global economic conditions, risks associated with data analysis and reporting,
and other risks as may be detailed from time to time in the Company&rsquo;s annual reports on Form 10-K and quarterly reports on
Form 10-Q and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligation
to revise the forward-looking statements or update them to reflect events or circumstances occurring after the date of this presentation,
whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Contact:</B><BR>
Sofia Warner<BR>
Senior Director, Investor Relations<BR>
Abeona Therapeutics<BR>
+1 (646) 813-4710<BR>
<FONT STYLE="color: Blue"><U>swarner@abeonatherapeutics.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact:</B><BR>
Scott Santiamo<BR>
Director, Corporate Communications<BR>
Abeona Therapeutics<BR>
+1 (718) 344-5843<BR>
<FONT STYLE="color: Blue"><U>ssantiamo@abeonatherapeutics.com</U></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] ,P# 2(  A$! Q$!_\0
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MRJ65LKU^5@W]*DNH%NK.:W8E5E1HR1U (Q3U"TKLJW6I+;:9'>>4SF38$C!
M)9R !GZFFPWM\;F*.YTTQ)(2/,28.%.,\C P..M/NM,2YTV.S\UT\O84D7&5
M9""#Z=14<6G7?VF*6YU.698F+"-8U0,<$<XZCGI2U$^:Y'J6M"PO8K58D:1X
MS)NEF6)  <=3U/M4UCJ+7D+2&#858K\CB16Z<AAUZT7VEO=SI-'=O"RKM*F-
F70\YSAAU]ZBM-"AMA*9)7EDE?>[ !!G ' 7 ' %'O7$^>^A__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
